Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 4Post-market surveillance

2(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

Terminated1

unknown1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 4

Trials by Phase

Phase 42 (100.0%)

Trials by Status

terminated133%

unknown133%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

NCT02964091

terminatedphase_4

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

NCT02717949

unknown

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods

NCT02657694

Clinical Trials (3)

Showing 3 of 3 trials

NCT02964091Phase 4

Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

Completed

NCT02717949Phase 4

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Terminated

NCT02657694

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods

Unknown

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3